中国团队实现系统性红斑狼疮靶向治疗新突破

格隆汇
5 hours ago
北京大学人民医院临床免疫中心主任、风湿免疫研究所所长栗占国牵头的国内多中心团队在《自身免疫杂志》六月刊发表布鲁顿酪氨酸激酶(BTK)抑制剂奥布替尼治疗系统性红斑狼疮(SLE)的研究成果,首次证实奥布替尼在活动性SLE患者中耐受性良好且具有确切疗效,标志着奥布替尼有望成为全球首个治疗SLE的BTK抑制剂。奥布替尼是一款在淋巴瘤领域多个适应症已经上市并已经使用5年多的口服药物,在中重度系统性红斑狼疮患者中,奥布替尼同样展现出显著疗效优势。这项研究目前已进展到奥布替尼治疗SLE的III期临床试验阶段,相关研究完成并获批上市后,将惠及更多患者。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10